MK0952 in Patients With Mild-to-Moderate Alzheimer's Disease

Merck Sharp & Dohme LLC0 个研究点目标入组 24 人开始时间: 2006年11月最近更新: 2016年5月16日

适应症

试验速览

阶段: 2 期
状态: 终止
发起方: Merck Sharp & Dohme LLC
入组人数: 24

研究概览研究设计入排标准研究者记录与标识符相似试验

研究概览

简要总结

MK0952 is a phosphodiesterase type IV (PDE4) inhibitor in development for improvement of cognitive impairment in mild-to-moderate Alzheimer's disease.

研究设计

研究类型: Interventional
分配方式: Randomized
干预模型: Crossover
主要目的: Treatment
盲法: Double (Participant, Investigator)

入排标准

年龄范围: 55 Years 至 —（Adult, Older Adult）
性别: All
接受健康志愿者: 否

入选标准

•Male or females
•Age >/= 55 years, With mild-to-moderate AD, with MMSE between 18 and 26, inclusive, MHIS score </= 4, Global CDR score of 1 or 2
•Who have a reliable informant/caregiver to accompany patient to all clinic visits
•If using a symptomatic AD treatments, patients must be on stable dose for >/= 6 months

排除标准

•Patients must not be living in nursing home or skilled nursing facility
•Patients must not have current evidence and/or history of Crohn's disease, ulcerative colitis, proctitis, GI bleeding, mesenteric arteritis
•Patients must not have current evidence and/or history of poorly-controlled hypertension, clinically significant cardiac arrhythmia, angina, or CHF
•Patients must not have current evidence and/or history of a psychotic disorder or major untreated depressive disorder
•Patients must not have current evidence and/or history of stroke or multiple lacunar infarcts, or neurological or neurodegenerative disorder (other than AD)
•Various concomitant therapy restrictions

研究者

发起方

Merck Sharp & Dohme LLC

申办方类型

Industry

责任方

Sponsor

相似试验

已完成

1 期

Safety, Blood Levels, Drug Interaction and Effects of Repeated Doses of GSK1034702Cognitive Disorders

NCT00950586GlaxoSmithKline48

已完成

1 期

Feasibility Study in Subjects With Mild to Moderate Alzheimer's DiseaseAlzheimer's Disease

NCT02560753T3D Therapeutics, Inc.36

已完成

不适用

Prevention of Cognitive Decline in ApoE4 Carriers With Subjective Cognitive Decline After EGCG and a Multimodal InterventionAlzheimer DiseaseCognitive Decline

NCT03978052Parc de Salut Mar129

已完成

1 期

Brain Uptake of GSK1034702: a Positron Emission Tomography (PET) Scan StudyCognitive Disorders

NCT00937846GlaxoSmithKline4

进行中（未招募）

不适用

Neurofeedback to Improve Working Memory in Mild Cognitive ImpairmentMild Cognitive Impairment

NCT04566900University of California, San Diego112